

## **Thrombolytic Dosing in PE: Versus Series References**

Special Guest: Lauren Igneri, PharmD, BCPS, BCCCP, FCCM

### **High-Risk/Massive PE**

Melamed R, Tierney DM, Xia R, et al. Safety and Efficacy of Reduced-Dose Versus Full-Dose Alteplase for Acute Pulmonary Embolism: A Multicenter Observational Comparative Effectiveness Study. *Crit Care Med*. 2024 May 1;52(5):729-742.

<https://pubmed.ncbi.nlm.nih.gov/38165776/>

Kiser TH, Burnham EL, Clark B, Ho PM, Allen RR, Moss M, Vandivier RW. Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism. *Crit Care Med*. 2018

Oct;46(10):1617-1625. <https://pubmed.ncbi.nlm.nih.gov/29979222/>

Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes García M, et al. Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. *J Thromb Thrombolysis*. 1995;2(3):227-229.

<https://pubmed.ncbi.nlm.nih.gov/10608028/>

Pollack CV, Schreiber D, Goldhaber SZ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). *J Am Coll Cardiol*. 2011 Feb 8;57(6):700-6.

<https://pubmed.ncbi.nlm.nih.gov/21292129/>

### **Intermediate-Risk/Submassive PE**

“MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). *Am J Cardiol*. 2013 Jan 15;111(2):273-7.

<https://pubmed.ncbi.nlm.nih.gov/23102885/>

Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. *N Engl J Med*. 2002 Oct 10;347(15):1143-50. <https://pubmed.ncbi.nlm.nih.gov/12374874/>

## **Cardiac Arrest**

Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. *N Engl J Med*. 2002 May 16;346(20):1522-8.

<https://pubmed.ncbi.nlm.nih.gov/12015391/>

Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012 Feb;141(2 Suppl):e419S-e496S.

<https://pubmed.ncbi.nlm.nih.gov/22315268/>

## **Thrombolytic Comparison**

PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med*. 2014 Apr 10;370(15):1402-11. <https://pubmed.ncbi.nlm.nih.gov/24716681/>

TROICA Trial Investigators; European Resuscitation Council Study Group. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. *N Engl J Med*. 2008 Dec 18;359(25):2651-62. <https://pubmed.ncbi.nlm.nih.gov/19092151/>

Melamed R, Tierney DM, Xia R, et al. Safety and Efficacy of Reduced-Dose Versus Full-Dose Alteplase for Acute Pulmonary Embolism: A Multicenter Observational Comparative Effectiveness Study. *Crit Care Med*. 2024 May 1;52(5):729-742.

<https://pubmed.ncbi.nlm.nih.gov/38165776/>

## **Review Articles**

Peters NA, Paciullo CA. Alteplase for the Treatment of Pulmonary Embolism: A Review. *Adv Emerg Nurs J*. 2015 Oct-Dec;37(4):258-72. <https://pubmed.ncbi.nlm.nih.gov/26509723/>

Igneri LA, Hammer JM. Systemic Thrombolytic Therapy for Massive and Submassive Pulmonary Embolism. *J Pharm Pract*. 2020 Feb;33(1):74-89.

<https://pubmed.ncbi.nlm.nih.gov/29673293/>